LifeStance Health Group, Inc.: Form 10-Q for the period ended Sep 30, 2021
Filed with the SEC on Nov 10, 2021 and accepted by EDGAR at Nov 10, 2021, 16:25 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-07-01 to 2021-09-30 | $173.8m | us-gaap:Revenues |
| Revenue | 9 months2021-01-01 to 2021-09-30 | $1.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Selling, general and administrative | 3 months2021-07-01 to 2021-09-30 | $162.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2021-01-01 to 2021-09-30 | $281.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2021-07-01 to 2021-09-30 | −$124.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2021-01-01 to 2021-09-30 | −$172.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-07-01 to 2021-09-30 | $3.5m | us-gaap:InterestExpense |
| Interest expense | 9 months2021-01-01 to 2021-09-30 | $35.3m | us-gaap:InterestExpense |
| Income tax | 3 months2021-07-01 to 2021-09-30 | −$8.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2021-01-01 to 2021-09-30 | −$15.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-07-01 to 2021-09-30 | −$120.5m | us-gaap:NetIncomeLoss |
| Net income | 9 months2021-01-01 to 2021-09-30 | −$199.2m | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months2021-01-01 to 2021-09-30 | −$21.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2021-01-01 to 2021-09-30 | $55.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-09-30 | $212.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-09-30 | $328.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-09-30 | $1.91bn | us-gaap:Assets |
| Current liabilities | At period end2021-09-30 | $105.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-09-30 | $369.9m | us-gaap:Liabilities |
| Long-term debt | At period end2021-09-30 | $157.4m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2021-09-30 | $1.3m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2021-09-30 | $1.54bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-21-004110. Last ingested by Listed: Nov 10, 2026, 19:02 ET. Listed shows no prices and gives no investment advice.